ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Ignace Vergote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.